Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

everolimus 5 MG Oral Tablet [Afinitor]

Known as: Afinitor 5 MG Oral Tablet 
 
National Institutes of Health

Related topics

Related topics

8 relations
Butylated HydroxytolueneCrospovidoneLactose MonohydrateMagnesium stearate
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in vitro and in a mouse model.
Infection with the larval stage (metacestode) of the fox tapeworm Echinococcus multilocularis leads to a primary hepatic disease… Expand
2015
2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line
Background: Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2014
2014
Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO
 
2013
2013
BRAWO - Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women
 
Review
2012
Review
2012
Pancreatic Neuroendocrine and Carcinoid Tumors: What’s New, What’s Old, and What’s Different?
Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs (panNETs). Recently, two… Expand
  • figure 1
Review
2011
Review
2011
Everolimus for the treatment of advanced renal cell carcinoma
  • R. Amato
  • Expert opinion on pharmacotherapy
  • 2011
    • Corpus ID: 19475319
Introduction: The efficacy of sequential everolimus (RAD001, Afinitor®), an orally administered inhibitor of mammalian target of… Expand
2011
2011
1167 POSTER Comparison of the Impact of the Targeted Therapy Everolimus (Afinitor®) and the Chemotherapy 5-FU on Cognitive Functions and Cerebral Plasticity in an Animal Model
 
Review
2009
Review
2009
Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms
ZusammenfassungDie letzten 5 Jahre waren durch grundlegende Veränderungen in der Systemtherapie des metastasierten… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE